• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Pacira BioSciences (PCRX) Is Up 7.7% After Positive Spine Pain Pilot Data and New FDA Clearance - Has The Bull Case Changed?

    Simply Wall St·12/15/2025 09:17:47
    Listen to the news
    • In early December 2025, Pacira BioSciences reported results from a 30-patient randomized pilot study comparing its ioveradeg cryoneurolysis to radiofrequency ablation for chronic low back pain, alongside recent FDA clearance of a new Smart tip designed for deeper lumbar nerve access.
    • The combination of encouraging comparative pain data and an FDA-cleared hardware enhancement highlights Pacira’s efforts to broaden ioveradeg’s role across spine-related pain pathways beyond its current indications.
    • We’ll now examine how the positive pilot study and new FDA-cleared Smart tip could influence Pacira’s broader investment narrative and outlook.

    The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

    Pacira BioSciences Investment Narrative Recap

    To own Pacira, you generally need to believe that non opioid pain solutions like EXPAREL, ZILRETTA and ioveradeg can support durable growth despite pricing, payer and patent pressures. The new ioveradeg pilot data and FDA cleared Smart tip modestly strengthen Pacira’s diversification story, but do not change that the most important short term catalyst remains execution on EXPAREL reimbursement and outpatient procedure volume, while dependence on EXPAREL and ongoing patent challenges still represent the biggest business risk.

    Against this backdrop, the recent CMS HCPCS coding update and 2025 J code expansion for EXPAREL look particularly relevant, because they support use in office and ambulatory settings at the same time Pacira is trying to build a broader non opioid portfolio that includes ioveradeg. Together, reimbursement expansion for EXPAREL and early spine related data for ioveradeg frame how much Pacira can reduce its reliance on a single product over time.

    However, investors should also be aware that if EXPAREL’s patent challenges or generic timing unfold differently than expected, the impact on...

    Read the full narrative on Pacira BioSciences (it's free!)

    Pacira BioSciences' narrative projects $908.9 million revenue and $112.0 million earnings by 2028. This requires 8.8% yearly revenue growth and about a $239.5 million earnings increase from -$127.5 million today.

    Uncover how Pacira BioSciences' forecasts yield a $29.00 fair value, a 10% upside to its current price.

    Exploring Other Perspectives

    PCRX 1-Year Stock Price Chart
    PCRX 1-Year Stock Price Chart

    Three Simply Wall St Community fair value estimates for Pacira span roughly US$29 to about US$161 per share, showing how far apart individual views can be. When you set those against Pacira’s reliance on EXPAREL and ongoing patent challenges, it underlines why many investors choose to weigh several different opinions before forming a view on the company’s longer term performance.

    Explore 3 other fair value estimates on Pacira BioSciences - why the stock might be worth over 6x more than the current price!

    Build Your Own Pacira BioSciences Narrative

    Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    Want Some Alternatives?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.